{ "ProductData": { "ID": "CPS_000012", "ProductType": "Others", "BrandName": "ASTPM", "ProductNameAddition": "Aspartate Aminotransferase acc. to IFCC with pyridoxal phosphate activation", "RegulatoryDisclaimer1": "For in vitro diagnostic use.", "DisclaimerGroup1": "IVD", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ "Serum", "Plasma" ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "" ], "ISOtypes": "", "Species": [ "" ], "StainLocalization": [ "" ], "ProductNameGlobal": "ASTPM" }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/Article_05531446190_im_en.png", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "01-0338", "StructureNodeStatus": "Active", "NodeName": "cobas AST" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "20-000-00", "StructureNodeStatus": "Active", "NodeName": "Assays Reagents and Strips" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "050-00", "StructureNodeStatus": "Active", "NodeName": "Core Lab" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "16-00-00", "StructureNodeStatus": "Active", "NodeName": "Hepatology" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "020", "StructureNodeStatus": "Active", "NodeName": "Clinical Chemistry" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "999-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "999", "StructureNodeStatus": "Active", "NodeName": "NOT APPLICABLE" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "45-00-00", "StructureNodeStatus": "Active", "NodeName": "Viral hepatitis" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "22-00-00", "StructureNodeStatus": "Active", "NodeName": "Liver cancer" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "10-00-00", "StructureNodeStatus": "Active", "NodeName": "Cardiology" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Indications", "StructureSystemName": "Indications", "NodeID": "99", "StructureNodeStatus": "Active", "NodeName": "Hepatology" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "05531446190", "MaterialDescription": "ASTPM, 740Tests, cobas c 701", "RegisteredProductName": "ASTPM", "GTIN": "04015630927418", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "740 tests", "PackSizeDescPIM360": "cobas c 701/702", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "INS_501", "BrandName": "cobas® c 701 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "310", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 701", "StructureGroupName": "cobas c 701", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_2177", "BrandName": "cobas® c 702 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "2492", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 702", "StructureGroupName": "cobas c 702", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "05535859001", "ProductName": "ALTPM / ASTPM", "ProductLongName": "Alanine Aminotransferase / Aspartate Aminotransferase acc. to IFCC with pyridoxal phosphate activation", "Language": "en", "DocumentVersion": "6", "DocumentObjectID": "FF000000058EB60E", "DocumentOriginID": "FF000000004D880E", "MaterialNumbers": [ "05531446190", "05531462190" ], "InstrumentReferences": [ { "ID": "2492", "BrandName": "cobas c 702" }, { "ID": "310", "BrandName": "cobas c 701" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) with pyridoxal phosphate activation in human serum and plasma on cobas c systems.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "", "Language": "en" }, { "Name": "MeasuringRange", "Value": "", "Language": "en" }, { "Name": "ExpectedValues", "Value": "", "Language": "en" }, { "Name": "LimitationInterference", "Value": "", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

ALTPM: 05531462190

R1:

780 tests

PYP:

780 tests

R3:

780 tests

ASTPM: 05531446190

R1:

740 tests

PYP:

740 tests

R3:

740 tests

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

ALTPM: ACN 8681, System‑ID 05 7462 6

ASTPM: ACN 8680, System‑ID 05 7461 8

", "Language": "en" }, { "Name": "Handling", "Value": "", "Language": "en" }, { "Name": "TestDefinition", "Value": "", "Language": "en" }, { "Name": "StorageStability", "Value": "", "Language": "en" }, { "Name": "Calibration", "Value": "", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "", "Language": "en" }, { "Name": "Reagents", "Value": "", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:
Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:
Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0005531446190c701", "ProductName": "ASTPM", "ProductLongName": "Aspartate Aminotransferase acc. to IFCC with pyridoxal phosphate activation", "Language": "en", "DocumentVersion": "13", "DocumentObjectID": "FF0000000587920E", "DocumentOriginID": "FF00000000313D0E", "MaterialNumbers": [ "05531446190" ], "InstrumentReferences": [ { "ID": "2492", "BrandName": "cobas c 702" }, { "ID": "310", "BrandName": "cobas c 701" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of aspartate aminotransferase (AST) with pyridoxal phosphate activation in human serum and plasma on cobas c systems.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

This assay follows the recommendations of the IFCC, but was optimized for performance and stability.

LREFBergmeyer HU, Hørder M, Rej R. Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC Method for aspartate aminotransferase. J Clin Chem Clin Biochem 1986;24:497-510.
,
LREFECCLS. Determination of the catalytic activity concentration in serum of L-aspartate aminotransferase (EC 2.6.1.1,ASAT). Klin Chem Mitt 1989;20:198-204.

AST in the sample catalyzes the transfer of an amino group between L‑aspartate and 2‑oxoglutarate to form oxaloacetate and L‑glutamate. The oxaloacetate then reacts with NADH, in the presence of malate dehydrogenase (MDH), to form NAD+. Pyridoxal phosphate serves as a coenzyme in the amino transfer reaction. It ensures full enzyme activation.

AST

L‑Aspartate + 2‑oxoglutarate

oxaloacetate + L‑glutamate

MDH

Oxaloacetate + NADH + H+

L‑malate + NAD+

The rate of the NADH oxidation is directly proportional to the catalytic AST activity. It is determined by measuring the decrease in absorbance.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

5‑700 U/L (0.08‑11.7 µkat/L)

Determine samples having higher activities via the rerun function. Dilution of samples via the rerun function is a 1:10 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 10.

Lower limits of measurement

Lower detection limit of the test

5 U/L (0.08 µkat/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from 0. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Values below the lower detection limit (< 5 U/L) will not be flagged by the instrument.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Acc. to IFCC/Standard Method 94 with pyridoxal phosphate activation measured at 37 °C:

LREFKlauke R, Schmidt E, Lorentz K. Recommendations for carrying out standard ECCLS procedures (1988) for the catalytic concentrations of creatine kinase, aspartate aminotransferase, alanine aminotransferase and γ-glutamyltransferase at 37 °C. Eur J Clin Chem Clin Biochem 1993;31:907-909.

Males:

10‑50 U/L

(0.17‑0.85 µkat/L)

Females:

10‑35 U/L

(0.17‑0.60 µkat/L)

Consensus values with pyridoxal phosphate activation:

LREFThomas L, Müller M, Schumann G, et al. Consensus of DGKL and VDGH for interim reference intervals on enzymes in serum. J Lab Med 2005; 29(5):301-308.

Males:

up to 50 U/L

(up to 0.85 µkat/L)

Females:

up to 35 U/L

(up to 0.60 µkat/L)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations - interference

Criterion: Recovery within ± 10 % of initial value at an AST activity of 35 U/L (0.58 µkat/L).

Icterus:

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 60 mg/dL or 1026 µmol/L).

Hemolysis:

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an H index of 20 (approximate hemoglobin concentration: 12.4 µmol/L or 20 mg/dL).

Contamination with erythrocytes will elevate results, because the analyte level in erythrocytes is higher than in normal sera. The level of interference may be variable depending on the content of analyte in the lysed erythrocytes.

Lipemia (Intralipid):

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an L index of 150. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Lipemic specimens may cause > Abs flagging.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug Effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Physiological plasma concentrations of Sulfasalazine or Sulfapyridine may lead to false results.

Cyanokit (Hydroxocobalamin) may cause interference with results.

In very rare cases, gammopathy, in particular type IgM (Waldenström’s macroglobulinemia), may cause unreliable results.

LREFBakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on cobas c systems. All special wash programming necessary for avoiding carry‑over is available via the cobas link, manual input is required in certain cases. The latest version of the carry‑over evasion list can be found with the NaOHD/SMS/SmpCln1+2/SCCS Method Sheet and for further instructions refer to the operator’s manual.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

05531446190

Aspartate Aminotransferase acc. to IFCC (740 tests)

System‑ID 05 7461 8

cobas c 701/702

Materials required (but not provided):

10759350190

Calibrator f.a.s. (12 x 3 mL)

Code 401

10759350360

Calibrator f.a.s. (12 x 3 mL, for USA)

Code 401

12149435122

Precinorm U plus (10 x 3 mL)

Code 300

12149435160

Precinorm U plus (10 x 3 mL, for USA)

Code 300

12149443122

Precipath U plus (10 x 3 mL)

Code 301

12149443160

Precipath U plus (10 x 3 mL, for USA)

Code 301

05117003190

PreciControl ClinChem Multi 1 (20 x 5 mL)

Code 391

05947626190

PreciControl ClinChem Multi 1 (4 x 5 mL)

Code 391

05947626160

PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)

Code 391

05117216190

PreciControl ClinChem Multi 2 (20 x 5 mL)

Code 392

05947774190

PreciControl ClinChem Multi 2 (4 x 5 mL)

Code 392

05947774160

PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)

Code 392

05172152190

Diluent NaCl 9 % (119 mL)

System‑ID 08 6869 3

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

ASTPM: ACN 8680

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Connect bottle containing pyridoxal phosphate to bottle R1 using the enclosed adapter and mix gently. Transfer the content to bottle R1. Pour the mixture into cassette position B.

R3 is ready for use.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for serum and plasma

cobas c 701/702 test definition

Assay type

Rate A

Reaction time / Assay points

10 / 29‑38

Wavelength (sub/main)

700/340 nm

Reaction direction

Decrease

Units

U/L (µkat/L)

Reagent pipetting

Diluent (H2O)

R1

60 µL

51  µL

R3

20 µL

20 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (NaCl)

Normal

9 µL

Decreased

9 µL

15 µL

135 µL

Increased

18 µL

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

ASTPM

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

2 weeks

On‑board on the Reagent Manager:

0 hours

Diluent NaCl 9 %

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

4 weeks

On‑board on the Reagent Manager:

24 hours

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: H2O

S2: C.f.a.s.

Calibration mode

Linear

Calibration frequency

2‑point calibration

- after reagent lot change

- as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the original IFCC formulation using calibrated pipettes together with a manual photometer providing absolute values and the substrate‑specific absorptivity, ε.

LREFSchumann G, Bonora R, Ceriotti F, et al. IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37 °C – Part 5. Reference Procedure for the Measurement of Catalytic Activity Concentrations of Aspartate Aminotransferase. Clin Chem Lab Med 2002;40(7):725-733.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 20 days). The following results were obtained:

Repeatability

Mean

U/L (µkat/L)

SD

U/L (µkat/L)

CV

%

Precinorm U

46.2 (0.772)

1.1 (0.018)

2.4

Precipath U

159 (2.66)

1 (0.02)

0.6

Human serum A

18.0 (0.301)

1.2 (0.020)

6.8

Human serum B

142 (2.37)

1 (0.02)

1.0

Human serum C

607 (10.1)

2 (0.0)

0.4

Intermediate precision

Mean

U/L (µkat/L)

SD

U/L (µkat/L)

CV

%

Precinorm U

49.0 (0.818)

0.8 (0.013)

1.6

Precipath U

149 (2.49)

1 (0.02)

0.8

Human serum 3

40.7 (0.680)

1.3 (0.022)

3.1

Human serum 4

190 (3.17)

3 (0.05)

1.3

Results for intermediate precision were obtained on the master system cobas c 501 analyzer.

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

AST values for human serum and plasma samples obtained on a cobas c 701 analyzer (y) were compared with those determined using the corresponding reagent on a cobas c 501 analyzer (x).

Sample size (n) = 308

Passing/Bablok

LREFBablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

Linear regression

y = 1.003x - 0.086 U/L

y = 0.993x + 0.468 U/L

τ = 0.888

r = 1.000

The sample activities were between 6.40 and 663 U/L (0.11 and 11.1 µkat/L).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary
LREFNagy B. Muscle disease. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry, theory, analysis, and correlation. St. Louis: Mosby 1984;514.
,
LREFMoss DW, Henderson AR, Kachmar JF. Enzymes. In: Tietz NW, ed. Fundamentals of Clinical Chemistry, 3rd ed. Philadelphia, PA: WB Saunders 1987;346-421.

The enzyme aspartate aminotransferase (AST) is widely distributed in tissue, principally hepatic, cardiac, muscle, and kidney. Elevated serum levels are found in diseases involving these tissues. Hepatobiliary diseases, such as cirrhosis, metastatic carcinoma, and viral hepatitis also increase serum AST levels. Following myocardial infarction, serum AST is elevated and reaches a peak 2 days after onset.

2 isoenzymes of AST have been detected, cytoplasmic and mitochondrial. Only the cytoplasmic isoenzyme occurs in normal serum, while the mitochondrial, together with the cytoplasmic isoenzyme, has been detected in the serum of patients with coronary and hepatobiliary disease.

The addition of pyridoxal phosphate to the assay causes an increase in aminotransferase activity. The activation is higher for AST than for ALT. Pyridoxal phosphate activation prevents falsely low aminotransferase activity in patient samples with insufficient endogenous pyridoxal phosphate (vitamin B6 deficiency).

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

R1

TRIS buffer: 264 mmol/L, pH 7.8 (37 °C); L‑aspartate: 792 mmol/L; MDH (microorganism): ≥ 24 µkat/L; LDH (microorganisms): ≥ 48 µkat/L; albumin (bovine): 0.25 %; preservative

Bottle

Pyridoxal phosphate: 730 µmol/L

R3 = cobas c pack position C

NADH: ≥ 1.7 mmol/L; 2‑oxoglutarate: 94 mmol/L; preservative

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:
Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:
Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum.

Plasma: Li‑heparin and K2‑EDTA plasma

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Stability:

LREFWHO Publication: Use of anticoagulants in diagnostic laboratory investigations, WHO/DIL/LAB/99.1 Rev.2:Jan 2002.

4 days at 20‑25 °C

7 days at 4‑8 °C

3 months at -20 °C

", "Language": "en" } ] } } ] }

ASTPM

Aspartate Aminotransferase acc. to IFCC with pyridoxal phosphate activation

IVD For in vitro diagnostic use.
ASTPM

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    Access Material Data Sheets, Certificates of Analysis, and other product documentation.

    After clicking below, you will be redirected to eLabDoc, where you can choose your local country.
    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later